Miniatura

Fitxers

GhoshN.pdf (633.32 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2016-09-10

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/125705

Reduced-intensity Transplantation For Lymphomas Using Haploidentical Related Donors Versus Hla-matched Sibling Donors: A Center For International Blood And Marrow Transplant Research Analysis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1200/JCO.2015.66.3476

Resum

Purpose: Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increasingly used in patients lacking HLA-matched sibling donors (MSD). We compared outcomes after Haplo-HCT using PT-Cy with MSD-HCT in patients with lymphoma, using the Center for International Blood and Marrow Transplant Research registry. Materials and Methods: We evaluated 987 adult patients undergoing either Haplo-HCT (n = 180) or MSD-HCT (n = 807) following reduced-intensity conditioning regimens. The haploidentical group received graft-versus-host disease (GVHD) prophylaxis with PT-Cy with or without a calcineurin inhibitor and mycophenolate. The MSD group received calcineurin inhibitor-based GVHD prophylaxis. Results: Median follow-up of survivors was 3 years. The 28-day neutrophil recovery was similar in the two groups (95% v 97%; P = .31). The 28-day platelet recovery was delayed in the haploidentical group compared with the MSD group (63% v 91%; P = .001). Cumulative incidence of grade II to IV acute GVHD at day 100 was similar between the two groups (27% v 25%; P = .84). Cumulative incidence of chronic GVHD at 1 year was significantly lower after Haplo-HCT (12% v 45%; P < .001), and this benefit was confirmed on multivariate analysis (relative risk, 0.21; 95% CI, 0.14 to 0.31; P < .001). For Haplo-HCT v MSD-HCT, 3-year rates of nonrelapse mortality (15% v 13%; P = .41), relapse/progression (37% v 40%; P = .51), progression-free survival (48% v 48%; P = .96), and overall survival (61% v 62%; P = .82) were similar. Multivariate analysis showed no significant difference between Haplo-HCT and MSD-HCT in terms of nonrelapse mortality (P = .06), progression/relapse (P = .10), progression-free survival (P = .83), and overall survival (P = .34). Conclusion: Haplo-HCT with PT-Cy provides survival outcomes comparable to MSD-HCT, with a significantly lower risk of chronic GVHD.

Matèries

Limfomes, Ciclofosfamida

Matèries (anglès)

Lymphomas, Cyclophosphamide

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GHOSH, Nilanjan, KARMALI, Reem, ROCHA, Vanderson, AHN, Kwang woo, DIGILIO, Alyssa, HARI, Parameswaran, BACHANOVA, Veronika, BACHER, Ulrike, DAHI, Parastoo b., LIMA, Marcos de, D'SOUZA, Anita, FENSKE, Timothy s., GANGULY, Siddhartha, KHARFAN-DABAJA, Mohamed a., PRESTIDGE, Tim d., SAVANI, Bipin n., SMITH, Sonali m., SUREDA, Anna, WALLER, Edmund k., JAGLOWSKI, Samantha, HERRERA, Alex f., ARMAND, Philippe, SALIT, Rachel b., WAGNER-JOHNSTON, Nina d., FUCHS, Ephraim, BOLANOS-MEADE, Javier, HAMADANI, Mehdi. Reduced-intensity Transplantation For Lymphomas Using Haploidentical Related Donors Versus Hla-matched Sibling Donors: A Center For International Blood And Marrow Transplant Research Analysis. _Journal of Clinical Oncology_. 2016. Vol. 34, núm. 26, pàgs. Pp 3141-3149. [consulta: 23 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/125705]

Exportar metadades

JSON - METS

Compartir registre